NIKKEI 225
28,845.74 +298.76 (+1.05%) HANG SENG
20,255.93 +80.31 (+0.40%) CRUDE OIL
91.67 -0.42 (-0.46%) GOLD FUTURES
1,814.00 -1.50 (-0.08%) DOW
33,761.05 +424.35 (+1.27%) BTC-GBP
20,306.63 -72.18 (-0.35%)
Cosmo Pharmaceuticals N.V. (0RGI.L)
| Previous close | 52.27 |
| Open | 52.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 52.34 - 52.61 |
| 52-week range | 52.34 - 52.61 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 7.71M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | 0.40 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results28-Jul-2022 / 06:06 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million
- EQS Group
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement28-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Ko
- EQS Group
Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement26-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea, a subsidiary
